When was glucagon first discovered?

Glucagon was formally isolated and identified in 1923 by Murlin and colleagues as a hyperglycaemic factor in pancreatic extracts. However, it remained largely a research curiosity for several decades until reliable purification and clinical applications emerged in the 1950s–1970s.

How long did it take glucagon to reach FDA approval?

Glucagon required approximately 50–60 years from initial discovery (1923) to FDA approval in the 1980s. The long timeline reflects the need for peptide chemistry advances, clinical trial data accumulation, and regulatory processes, though approval accelerated once evidence was mature.

Is glucagon approved outside the US?

Yes. Glucagon holds regulatory approval in the EU (EMA-authorised), Canada (Health Canada approved), and many other countries. All approvals cover emergency treatment of severe hypoglycaemia, and modern formulations (including nasal spray and auto-injectors) are widely available globally.

What is glucagon's primary approved use?

Glucagon is FDA-, EMA-, and Health Canada-approved as an emergency treatment for severe hypoglycaemia (dangerous low blood sugar) in people taking insulin. It works by signalling the liver to release glucose, rapidly raising blood sugar levels during acute hypoglycaemic episodes.

Are there new glucagon formulations in development?

Yes. Over 1,000 clinical trials have investigated glucagon, including advanced delivery systems like nasal sprays, pen-injectors, and combination therapies. These focus on improving ease of use and exploring potential roles beyond emergency hypoglycaemia, though approvals remain focused on the established emergency indication.

Glucagon Regulatory History: Timeline & Approvals

Glucagon is an FDA-approved peptide hormone with one of the longest regulatory histories in medicine—stretching back nearly a century to its initial discovery in 1923. This timeline traces glucagon's evolution from laboratory curiosity to a critical emergency medicine staple, documenting the clinical trials, regulatory submissions, and scientific breakthroughs that shaped its path to approval across the US, EU, and Canada. With over 1,000 clinical trials investigating its mechanisms and applications, glucagon remains one of the most thoroughly studied peptides in medical history.

The Early Years: 1923–1950

Glucagon's story begins in the 1920s when researchers first identified a hyperglycemic (blood sugar-raising) factor in pancreatic extracts. The compound was formally isolated and characterised by Murlin and colleagues in 1923, marking the birth of glucagon science. For decades, however, the peptide remained largely a research curiosity—difficult to extract, unstable, and poorly understood.

The early research established glucagon's fundamental role: it acts as the body's counter-regulatory hormone to insulin, signalling the liver to release glucose during fasting or stress. This opposing mechanism made it theoretically valuable for treating severe hypoglycaemia (dangerously low blood sugar), but practical applications remained elusive.

The Clinical Breakthrough Era: 1950s–1970s

The turning point came with advances in peptide chemistry and purification. By the 1950s, researchers had developed reliable methods to extract and stabilise glucagon from pancreatic tissue. Early clinical studies demonstrated that injected glucagon could rapidly restore blood glucose levels in hypoglycaemic patients, opening the door to therapeutic use.

Throughout the 1960s and 1970s, glucagon accumulated clinical evidence:

Studies in diabetic patients showed consistent, rapid reversal of severe hypoglycaemic episodes
Researchers documented its safety profile across diverse populations
The peptide's short half-life (3–10 minutes) was recognised as both an advantage (rapid reversal of overdose risk) and limitation (short duration of action)

This era saw the foundation of glucagon's regulatory case: abundant clinical data supporting efficacy and safety in a life-threatening emergency condition.

FDA Approval and Regulatory Milestones: 1980s–1990s

Gluagon received FDA approval as an injectable emergency treatment for severe hypoglycaemia, cementing its status as a critical diabetes management tool. The approval was grounded in decades of clinical evidence and the clear unmet need in emergency medicine.

By the 1990s, glucagon had become standard protocol in hospital emergency departments, ambulance services, and in-home diabetes kits. Regulatory agencies in Canada and the European Union followed with their own approvals, making glucagon a truly international therapeutic standard.

Key Regulatory Features:

US: FDA-approved for emergency treatment of severe hypoglycaemia in insulin-dependent diabetics
EU: EMA-authorised for the same indication across European member states
Canada: Health Canada approved glucagon for emergency hypoglycaemia management

Formulation Evolution: 2000s–2010s

While the active peptide remained unchanged, pharmaceutical innovation focused on delivery systems and ease of use. Traditional glucagon required reconstitution—mixing a powder with a liquid before injection, which created barriers during emergencies.

Nasal glucagon formulations entered clinical development in the 2000s, aimed at simplifying administration in non-medical settings. These studies demonstrated that intranasal delivery could achieve similar blood glucose restoration without the need for injection, potentially expanding glucagon's accessibility.

GLP-1 receptor agonists (like semaglutide) also emerged in this period as weight-loss agents, reigniting scientific interest in the glucagon pathway and its broader metabolic effects—though glucagon itself remained primarily positioned for emergency use.

Modern Clinical Research: 2010s–Present

Over the past 15 years, clinical research has exploded. More than 1,000 clinical trials investigating glucagon have been registered, spanning:

Emergency Hypoglycaemia Management

Recent trials continue to confirm glucagon's efficacy and safety profile in acute hypoglycaemic episodes across diverse patient populations, from young children to elderly patients with comorbidities.

Investigational Applications

Research has expanded into novel territories:

Glucagon in combination with insulin: Animal studies suggest co-administration may improve glycaemic control in type 1 diabetes
Post-bariatric hypoglycaemia: Preclinical data indicates glucagon may help manage reactive hypoglycaemia after weight-loss surgery
Metabolic research: Investigation of glucagon's broader role in appetite regulation and energy expenditure

These exploratory uses remain in research phases and have not yet resulted in new FDA approvals, though they highlight the peptide's broader therapeutic potential.

Advanced Delivery Systems

Clinical trials of pen-injectors, nasal formulations, and combination products have modernised glucagon administration, reducing preparation time and improving real-world usability in emergency settings.

Regulatory Status Today

Gluacon holds firm regulatory approval across major markets:

| Region | Status | Primary Indication | |--------|--------|--------------------| | USA (FDA) | Approved | Emergency treatment of severe hypoglycaemia | | EU (EMA) | Authorised | Emergency treatment of severe hypoglycaemia | | Canada (Health Canada) | Approved | Emergency treatment of severe hypoglycaemia |

Approved formulations are available as:

Injectable powder (requires reconstitution)
Nasal spray (ready-to-use)
Auto-injector pens (pre-filled, single-dose)

The Research Landscape

With 1,000+ clinical trials and counting, glucagon remains one of the most intensively studied peptides in medical history. Active research areas include:

Optimising dual-hormone (insulin + glucagon) systems for type 1 diabetes management
Understanding glucagon's role in appetite and satiety (adjacent to GLP-1 research)
Developing next-generation formulations for improved patient experience
Exploring combination therapies with other metabolic peptides

These studies build on glucagon's rock-solid foundation of safety and efficacy in emergency settings, exploring whether the peptide can unlock value in new clinical contexts.

Why This History Matters

Gluagon's regulatory journey reflects a century of scientific progress:

Fundamental research (1920s–1950s) identified the peptide and its mechanism
Clinical validation (1950s–1980s) proved safety and efficacy
Regulatory approval (1980s onwards) made it standard of care
Modern innovation (2010s–present) continues refining delivery and exploring new applications

Few peptides have such a long, well-documented history of approval and clinical use. Glucagon's status as a proven, widely available emergency medicine reflects decades of rigorous science and regulatory scrutiny.

Future Directions

While glucagon's core emergency role is secure, the next chapter may involve:

Integration into hybrid closed-loop diabetes management systems
Investigation of metabolic effects beyond glucose regulation
Combination with newer peptide therapies (like tirzepatide or semaglutide)
Enhanced formulations improving real-world accessibility

The regulatory pathway is already well-established; future approvals will likely focus on delivery innovation and novel indication expansion rather than fundamental efficacy questions.

Glucagon Regulatory History: From Discovery to Modern Medicine